Literature DB >> 20502017

Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort.

Maarten Liedorp1, Cornelis J Stam, Wiesje M van der Flier, Yolande A L Pijnenburg, Philip Scheltens.   

Abstract

BACKGROUND: Although EEG is not considered as standard in memory clinics, evidence indicates that epileptiform discharges are of value in diagnosing cognitive complaints as epilepsy.
OBJECTIVE: To determine prevalence and significance of epileptiform discharges in a memory clinic.
METHODS: 1,674 consecutive patients underwent routine EEGs [mean age 66 years, diagnoses: Alzheimer disease (AD; n = 510), other dementia (n = 193), mild cognitive impairment (MCI; n = 225), subjective complaints (n = 368), and other disorders (n = 378)]. Database statistics, charts and EEG reports were reviewed.
RESULTS: Epileptiform discharges were present in 42 (3%) patients, of which 60% lacked clinical seizures. All discharges were focal and predominantly temporally localized. Epileptiform activity was not associated with a dementia diagnosis (2% in AD and 1% in other dementia vs. 2% in MCI, 2% in subjective complaints and 5% in other disorders, p = 0.07) or with lower Mini-Mental State Examination scores (p = 0.69). Two (diagnoses: AD, vascular dementia) of 20 patients with epileptiform activity without clinical seizures developed first seizures after 2 years.
CONCLUSION: In a memory clinic cohort, epileptiform discharges are rare, nonspecific and indicate a moderate risk of first-ever seizures in demented patients. These findings should be taken into account when routinely evaluating memory clinic patients with EEG.

Entities:  

Mesh:

Year:  2010        PMID: 20502017     DOI: 10.1159/000278620

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  21 in total

Review 1.  Seizures and epilepsy in Alzheimer's disease.

Authors:  Daniel Friedman; Lawrence S Honig; Nikolaos Scarmeas
Journal:  CNS Neurosci Ther       Date:  2011-06-07       Impact factor: 5.243

2.  Seizures and epileptiform activity in the early stages of Alzheimer disease.

Authors:  Keith A Vossel; Alexander J Beagle; Gil D Rabinovici; Huidy Shu; Suzee E Lee; Georges Naasan; Manu Hegde; Susannah B Cornes; Maya L Henry; Alexandra B Nelson; William W Seeley; Michael D Geschwind; Maria L Gorno-Tempini; Tina Shih; Heidi E Kirsch; Paul A Garcia; Bruce L Miller; Lennart Mucke
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

Review 3.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

Review 4.  [Alzheimer's disease and epilepsy].

Authors:  R Haussmann; T Mayer; W Schrempf; M Donix
Journal:  Nervenarzt       Date:  2017-09       Impact factor: 1.214

5.  Widespread changes in network activity allow non-invasive detection of mesial temporal lobe seizures.

Authors:  Alice D Lam; Rodrigo Zepeda; Andrew J Cole; Sydney S Cash
Journal:  Brain       Date:  2016-07-29       Impact factor: 13.501

6.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.

Authors:  Keith A Vossel; Kamalini G Ranasinghe; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Anne F Dowling; Sonja M Darwish; Victoria Van Berlo; Deborah E Barnes; Mary Mantle; Anna M Karydas; Giovanni Coppola; Erik D Roberson; Bruce L Miller; Paul A Garcia; Heidi E Kirsch; Lennart Mucke; Srikantan S Nagarajan
Journal:  Ann Neurol       Date:  2016-11-07       Impact factor: 10.422

7.  Seizures in Alzheimer disease: clinical and epidemiological data.

Authors:  Dionysios Pandis; Nikolaos Scarmeas
Journal:  Epilepsy Curr       Date:  2012-09       Impact factor: 7.500

8.  The predictive value of normal EEGs in dementia due to Alzheimer's disease.

Authors:  Casper T Briels; Cornelis J Stam; Philip Scheltens; Alida A Gouw
Journal:  Ann Clin Transl Neurol       Date:  2021-04-09       Impact factor: 4.511

9.  Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model.

Authors:  Haakon B Nygaard; Adam C Kaufman; Tomoko Sekine-Konno; Linda L Huh; Hilary Going; Samantha J Feldman; Mikhail A Kostylev; Stephen M Strittmatter
Journal:  Alzheimers Res Ther       Date:  2015-05-05       Impact factor: 6.982

10.  Ascorbate deficiency decreases dopamine release in gulo-/- and APP/PSEN1 mice.

Authors:  David C Consoli; Lillian J Brady; Aaron B Bowman; Erin S Calipari; Fiona E Harrison
Journal:  J Neurochem       Date:  2020-09-21       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.